Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies.
Humans
Percutaneous Coronary Intervention
/ adverse effects
Cytochrome P-450 CYP2C19
/ genetics
Registries
Precision Medicine
/ methods
Platelet Aggregation Inhibitors
/ administration & dosage
Clopidogrel
/ administration & dosage
Ticagrelor
/ administration & dosage
Prasugrel Hydrochloride
/ administration & dosage
Dual Anti-Platelet Therapy
/ methods
Aspirin
/ administration & dosage
Purinergic P2Y Receptor Antagonists
/ administration & dosage
Hemorrhage
/ chemically induced
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
01
08
2024
received:
06
05
2024
accepted:
06
08
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
ppublish
Résumé
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y
Substances chimiques
Cytochrome P-450 CYP2C19
EC 1.14.14.1
CYP2C19 protein, human
EC 1.14.14.1
Platelet Aggregation Inhibitors
0
Clopidogrel
A74586SNO7
Ticagrelor
GLH0314RVC
Prasugrel Hydrochloride
G89JQ59I13
Aspirin
R16CO5Y76E
Purinergic P2Y Receptor Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70004Informations de copyright
© 2024 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347‐e913.
Angiolillo DJ, Galli M, Collet JP, Kastrati A, O'Donoghue ML. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention. 2022;17:e1371‐e1396.
Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non‐responders compared with clopidogrel in aspirin‐treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166‐1173.
Gurbel PA, Bliden KP, Butler K, et al. Randomized double‐blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577‐2585.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001‐2015.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045‐1057.
Lawton JS, Tamis‐Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145:e4‐e17.
Dayoub EJ, Seigerman M, Tuteja S, et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet‐naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern Med. 2018;178:943‐950.
Zanchin T, Temperli F, Karagiannis A, et al. Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the Bern percutaneous coronary intervention registry. Circ Cardiovasc Interv. 2018;11:e006132.
Ijaz SH, Baron SJ, Shahnawaz A, et al. Utilization trends in platelet adenosine diphosphate P2Y12 receptor inhibitor and cost among Medicare beneficiaries. Curr Probl Cardiol. 2023;48:101608.
Wang Y, Cavallari LH, Brown JD, Thomas CD, Winterstein AG. Assessing the clinical treatment dynamics of antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention in the US. JAMA Netw Open. 2023;6:e238585.
Lee CR, Luzum JA, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and Clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112:959‐967.
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p‐450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354‐362.
Mega JL, Simon T, Collet JP, et al. Reduced‐function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta‐analysis. JAMA. 2010;304:1821‐1830.
Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119:2553‐2560.
Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320‐1328.
Weitzel KW, Elsey AR, Langaee TY, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet. 2014;166C:56‐67.
Lee JA, Lee CR, Reed BN, et al. Implementation and evaluation of a CYP2C19 genotype‐guided antiplatelet therapy algorithm in high‐risk coronary artery disease patients. Pharmacogenomics. 2015;16:303‐313.
Cavallari LH, Franchi F, Rollini F, et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med. 2018;16:92.
Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti‐platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet. 2014;166C:76‐84.
Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype‐guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11:181‐191.
Beitelshees AL, Thomas CD, Empey PE, et al. CYP2C19 genotype‐guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings. J Am Heart Assoc. 2022;11:e024159.
Pereira NL, Farkouh ME, So D, et al. Effect of genotype‐guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR‐PCI randomized clinical trial. JAMA. 2020;324:761‐771.
Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype‐guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621‐1631.
Masoudi FA, Ponirakis A, de Lemos JA, et al. Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries. J Am Coll Cardiol. 2017;69:1427‐1450.
Nguyen AB, Cavallari LH, Rossi JS, Stouffer GA, Lee CR. Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype‐guided antiplatelet therapy. Front Cardiovasc Med. 2022;9:991646.
Capodanno D, Mehran R, Krucoff MW, et al. Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium. Circulation. 2023;147:1933‐1944.
Empey PE, Stevenson JM, Tuteja S, et al. Multisite investigation of strategies for the implementation of CYP2C19 genotype‐guided antiplatelet therapy. Clin Pharmacol Ther. 2018;104:664‐674.
Development of Standards for the Collection of Socioeconomic Status in Health Surveys Conducted by the Department of Health and Human Services. Accessed May 6, 2024. https://www.ncvhs.hhs.gov/wp‐content/uploads/2014/05/120622lt.pdf
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377‐381.
Thomas CD, Franchi F, Keeley EC, et al. Impact of the ABCD‐GENE score on Clopidogrel clinical effectiveness after PCI: a multi‐site, real‐world investigation. Clin Pharmacol Ther. 2022;112:146‐155.
Thomas Cameron D, Franchi F, Rossi Joseph S, et al. Effectiveness of Clopidogrel vs alternative P2Y12 inhibitors based on the ABCD‐GENE score. J Am Coll Cardiol. 2024;83:1370‐1381.
Tunehag KR, Thomas CD, Franchi F, et al. CYP2C19 genotype is associated with adverse cardiovascular outcomes in black patients treated with Clopidogrel undergoing percutaneous coronary intervention. J Am Heart Assoc. 2024;13:e033791.
AlSaeed MJ, Thomas CD, Franchi F, et al. Evaluating the effect of estimating renal function with the CKD‐EPI 2021 equation on the ABCD‐GENE score for Clopidogrel response prediction. Clin Pharmacol Ther. 2024. Epub ahead of print. doi:10.1002/cpt.3385
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736‐2747.
Hicks KA, Mahaffey KW, Mehran R, et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961‐972.
Garcia‐Garcia HM, McFadden EP, Farb A, et al. Standardized end point definitions for coronary intervention trials: the academic research Consortium‐2 consensus document. Circulation. 2018;137:2635‐2650.
Zhang Y, Shi XJ, Peng WX, et al. Impact of implementing CYP2C19 genotype‐guided antiplatelet therapy on P2Y(12) inhibitor selection and clinical outcomes in acute coronary syndrome patients after percutaneous coronary intervention: a real‐world study in China. Front Pharmacol. 2020;11:582929.
Leyrat C, Seaman SR, White IR, et al. Propensity score analysis with partially observed covariates: how should multiple imputation be used? Stat Methods Med Res. 2019;28:3‐19.
Cresci S, Depta JP, Lenzini PA, et al. Cytochrome p450 gene variants, race, and mortality among clopidogrel‐treated patients after acute myocardial infarction. Circ Cardiovasc Genet. 2014;7:277‐286.
Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to Clopidogrel: the ABCD‐GENE score. JACC Cardiovasc Interv. 2020;13:606‐617.
Pendyala LK, Torguson R, Loh JP, et al. Racial disparity with on‐treatment platelet reactivity in patients undergoing percutaneous coronary intervention. Am Heart J. 2013;166:266‐272.
Bucholz EM, Ma S, Normand SL, Krumholz HM. Race, socioeconomic status, and life expectancy after acute myocardial infarction. Circulation. 2015;132:1338‐1346.
De Luca L, D'Ascenzo F, Musumeci G, et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention. 2017;13:459‐466.
Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12‐receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13:11‐27.
Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070‐3078.
Sibbing D, Aradi D, Jacobshagen C, et al. Guided de‐escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL‐ACS): a randomised, open‐label, multicentre trial. Lancet. 2017;390:1747‐1757.
Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12:1521‐1537.
Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849‐857.
Lewis JP, Backman JD, Reny JL, et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel‐treated patients. Eur Heart J Cardiovasc Pharmacother. 2020;6:203‐210.